Journal article icon

Journal article

Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies.

Abstract:

PURPOSE: To determine efficacy and safety of intravitreal aflibercept in patients with neovascular age-related macular degeneration (AMD) during a second year of variable dosing after a first-year fixed-dosing period. DESIGN: Two randomized, double-masked, active-controlled, phase 3 trials. PARTICIPANTS: Two thousand four hundred fifty-seven patients with neovascular AMD. METHODS: From baseline to week 52, patients received 0.5 mg intravitreal ranibizumab every 4 weeks (Rq4), 2 mg aflibercept...

Expand abstract
Publication status:
Published

Actions


Access Document


Authors


Schmidt-Erfurth, U More by this author
Kaiser, PK More by this author
Korobelnik, JF More by this author
More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Clinical Neuroscience
Expand authors...
Journal:
Ophthalmology
Volume:
121
Issue:
1
Pages:
193-201
Publication date:
2014-01-05
DOI:
EISSN:
1549-4713
ISSN:
0161-6420
URN:
uuid:71c49da6-e786-47ca-98ce-7a9927a2b90c
Source identifiers:
431062
Local pid:
pubs:431062

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP